Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Ca...(how that TPI 287 is unsafeand/or ineffec...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
Date:11/5/2007
how that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 28, 2007, June 27, 2007 and September 26, 2007. The Company cautions investors not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.
For further information, please contact Gordon Link, Senior Vice President, Chief Financial Officer, at 303-516-8500.
Contact:
Tapestry Pharmaceuticals, Inc.
Gordon Link
Senior Vice President, Chief Financial Officer
303-516-8500
Investor:
Lilian Stern
Stern Investor Relations, Inc.
212-362-1200
Media:
Dana Conti
Schwartz Communications
781-684-0770
tapestry@schwartz-pr.com
Tapestry Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(In thou
'/>"/>
| SOURCE Tapestry Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Tapestry to Host Conference Call on November 5th to Discuss Third Quarter 2007 Financial Results
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
Breaking Biology Technology:Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 2BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 3
[0] Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease[0] Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease[0] MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products[0] BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes
Other Biology Technology:Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 2Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 3Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 4
Breaking Biology News(10 mins):Studying hair of ancient Peruvians answers questions about stress 2Study confirms association between tobacco smoke and behavioral problems in children 2CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2UT Southwestern physicians bust myths about insulin 54134 1UT Southwestern physicians bust myths about insulin 54134 2Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock 13480 1Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock 13480 2Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 1Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 2Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 3Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 4Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 5Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 54127 6
Other Biology News:Telemedicine robots help improve health 2Air travel and flu: Post-9/11 restrictions delayed start of season 2
Biology Products:
Mouse Anti-p14 ARF / p16Beta Ab-2 Mouse Monoclonal Antibody, Unconjugated, Clone 14P02 from Lab Vision10 x ReddyRun Gel Loading Buffer from ABgeneAnti-Acetylcholinesterase Monoclonal Antibody, Unconjugated, Clone AE-2 from CHEMICONMouse Anti-IgG2 (Fc, gamma-2 epitope) Monoclonal Antibody, Unconjugated, Clone 52G1 from Meridian Life Science, Inc.
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |